Every Form 4 that LeMaitre Vascular, Inc. (LMAT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LMAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LMAT filings page.
LeMaitre Vascular Inc disclosed insider equity transactions by its Senior V. P., Operations in December 2025. The officer acquired small amounts of common stock through the release of dividend equivalent rights on 12/11/2025 and 12/12/2025, with each right economically equivalent to one share of common stock.
On those dates, the issuer also withheld 90 shares on three separate occasions to satisfy tax withholding obligations tied to the vesting of restricted stock units and performance stock units originally granted in 2021 and 2022. After these transactions, the officer beneficially owned 4,417 shares of common stock directly.
LeMaitre Vascular, Inc. director filed a report of routine equity-related transactions. On 12/11/2025 and 12/12/2025, the director acquired 25, 18, and 18 shares of common stock at a price of $0 per share following the release of dividend equivalent rights tied to prior stock awards. After these transactions, the director directly beneficially owned 10,183 shares of common stock.
The filing shows dividend equivalent rights converting into common stock on a one-for-one basis, connected to restricted stock unit and performance stock unit awards granted in 2021 and 2022. Fractional shares from these rights, if any, were settled in cash, leaving derivative right balances such as 19.974 and 19.291 units outstanding.
LeMaitre Vascular, Inc. disclosed that a director acquired common stock through the vesting of equity-based awards on 12/12/2025. Two transactions converted derivative awards into common stock, each for 5 shares of common stock at a price of $0 per share under transaction code "M," which typically reflects the exercise or conversion of derivative securities.
The new shares came from the release of dividend equivalent rights that were tied to restricted stock unit and performance stock unit awards originally granted on 12/12/2022. Each dividend equivalent right was the economic equivalent of one share of LeMaitre Vascular common stock, and any fractional shares were settled in cash, leaving no remaining dividend equivalent rights outstanding after these vesting events.
A LeMaitre Vascular director reported automatic share acquisitions tied to existing equity awards. On 12/12/2025, dividend equivalent rights linked to stock awards converted into common shares at an exercise price of $0, with the transactions coded as exercises (code M). The director received 5 shares from dividend equivalent rights associated with a restricted stock unit award granted on 12/12/2022 and another 5 shares from rights linked to a performance stock unit award granted on the same date. Fractional shares from these rights, if any, were settled in cash, leaving a remaining balance of 0 dividend equivalent rights.
A LeMaitre Vascular Inc. director reported stock transactions tied to dividend equivalent rights that vested on 12/12/2025. The director acquired 5 shares of common stock in each of two transactions at a price of $0 per share, reflecting the release of dividend equivalent rights on a one-for-one basis into common stock.
Following these transactions, the director beneficially owned 62,350 shares of LeMaitre Vascular common stock directly. The derivative positions shown were dividend equivalent rights linked to restricted stock unit and performance stock unit awards granted on 12/12/2022, each right being the economic equivalent of one share. After vesting, the number of these derivative rights was reduced to zero, with any fractional shares settled in cash.
LeMaitre Vascular director Lawrence J. Jasinski reported the release and exercise of dividend equivalent rights on 2025-12-12, converting those rights into 10 shares of common stock at $0.0000 per share in connection with vesting of 2022 restricted and performance stock unit awards. Fractional share amounts, if any, were settled in cash, leaving no remaining dividend equivalent rights. Following these transactions, he directly holds 5,322 shares of common stock.
LeMaitre Vascular director John A. Roush exercised dividend equivalent rights on 12/12/2025, converting a total of 10 rights into an equal number of common shares at $0.0000 per share. After these conversions he holds 3,465 LMAT shares directly and 181.0000 shares indirectly through his spouse. Footnotes explain that these rights were released upon vesting of restricted and performance stock unit awards granted on 12/12/2022, with any fractional rights settled in cash.
LeMaitre Vascular reported an equity grant to its Senior Vice President of Operations. On 12/10/2025, the executive received 1,177 shares of common stock as a restricted stock unit award at a stated price of $0, bringing direct beneficial ownership of common stock to 4,660 shares.
The executive also received a stock option covering 7,222 shares of common stock at an exercise price of $83.66 per share, expiring on 12/10/2032. The restricted stock units vest 25% on 12/1/2026, with the remainder vesting in equal annual installments over the following three years, and the issuer may withhold shares to satisfy tax obligations. The option vests over four years, with 25% vesting on the first anniversary of the grant date and the balance in equal annual installments over the next three years.
LeMaitre Vascular Inc's chief financial officer reported receiving new equity awards in the company’s stock. On 12/10/2025, the officer acquired 1,177 shares of common stock at a stated price of $0, bringing direct ownership to 2,398 common shares.
The filing also shows a new stock option grant for 7,222 shares with an exercise price of $83.66 and an expiration date of 12/10/2032. The 1,177-share award is structured as restricted stock units that vest 25% on 12/1/2026, with the rest vesting in equal annual installments over the following three years. The option vests over four years at 25% on the first anniversary of the grant date listed, with the balance vesting in equal annual installments over the next three years.
LeMaitre Vascular Inc. disclosed that its president and director received new equity awards. On 12/10/2025, the insider acquired 1,694 shares of common stock as a restricted stock unit award at a price of $0, bringing total common stock beneficially owned to 23,091 shares held directly.
The insider was also granted a stock option for 10,400 shares of common stock with an exercise price of $83.66, expiring on 12/10/2032. The restricted stock units vest 25% on 12/1/2026, with the remainder vesting in equal annual installments over three years, and include share withholding to cover taxes. The option vests 25% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following three years.
LeMaitre Vascular Inc reported that a company director received new equity awards in the form of common stock and stock options. On 12/10/2025, the director acquired 533 shares of common stock through a restricted stock unit award at a price of $0 per share, bringing direct beneficial ownership to 62,340 shares.
The disclosure also shows stock options covering 3,431 shares of common stock with an exercise price of $83.66 and an expiration date of 12/10/2030. The restricted stock units vest 33 1/3% on 12/1/2026, with the remainder vesting in equal annual installments over the next two years, while the options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following two years.
LeMaitre Vascular reported that one of its directors received new equity awards. On 12/10/2025 the director was granted 533 restricted stock units of common stock at a price of $0 and 3,431 stock options with an exercise price of $83.66 per share.
The restricted stock units vest 33 1/3% on 12/1/2026, with the rest vesting in equal annual installments over the following two years. The options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the remaining two years, and expire on 12/10/2030. After this grant, the director beneficially owns 3,455 common shares directly, 181 shares indirectly through a spouse, and 3,431 options.
LeMaitre Vascular reported insider equity transactions by its Senior Vice President, Operations on a Form 4. On 12/06/2025, 2 shares of common stock were acquired at $0 per share upon the release of dividend equivalent rights, bringing direct holdings before tax withholding to 3,712 shares. Also on that date, 69 shares were disposed of at $84.53 per share as shares withheld by the issuer to satisfy tax withholding obligations from previously awarded restricted stock units, resulting in 3,643 common shares owned directly.
The report also shows several acquisitions of dividend equivalent rights on 12/04/2025 that accrued on restricted stock unit and performance share unit awards originally granted on 12/11/2021, 12/12/2022, 12/8/2023, and 12/6/2024. Each dividend equivalent right is stated to be the economic equivalent of one share of LeMaitre Vascular common stock and to vest proportionately with the related awards.
LeMaitre Vascular, Inc. (LMAT) reported an insider equity transaction by a director. On 11/21/2025, the reporting person exercised a stock option to buy 7,500 shares of common stock at an exercise price of $37.29 per share, as shown in Table II. These shares, reported in Table I, were acquired and increased the director’s directly owned common stock holdings to 64,801 shares following the transaction. The option, originally granted on 12/02/2020 and fully vested and exercisable, was due to expire on 12/02/2025 and shows 0 derivative securities remaining from this grant after the exercise.
LeMaitre Vascular, Inc. (LMAT) Chairman and CEO, who is also a director, reported an insider transaction on 11/20/2025. He exercised a stock option to buy 2,681 shares of common stock at an exercise price of $41.02 per share, converting a derivative position into directly owned stock. After this exercise, he directly beneficially owns 1,665,984 shares of LeMaitre Vascular common stock.
In addition, 21,300 shares are held indirectly through the “LeMaitre Irrevocable Life Insurance Trust of 2025” for the benefit of his child or children. He disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest. The option that was exercised covered 2,681 shares, was fully vested and exercisable, and now shows 0 derivative securities remaining from that grant.